Boston-based eye tracking company SyncThink has made major changes to its marketing materials since the FDA objected to its labeling in a warning letter. The letter is dated July 31st; MedCityNews first spotted the missive.
"Specifically, the EYE-SYNC device was cleared as a prescription device under K152915 with the following indications for use: recording, viewing, and analyzing eye movements...
SyncThink, a Boston-based applying VR and eye-tracking to assess ability to focus as an indicator of concussion damage, has launched the next generation of its FDA-cleared EYE-SYNC platform.
“Concussion is the most underreported, underdiagnosed, and underestimated type of brain trauma,” CEO Ernest Santin said in a statement. “There is no universally accepted, evidence-based definition of...
Eye-tracking and gesture sensors are set to mark the next stage of innovation in machine design, according to new data from ABI Research. Just like touchscreens took over where the hand-controlled PC mouse left off, sensor technology is will change the way people interact with machines and systems. Bolstered by the ability to integrate with smartphone and tablet sensors, ABI forecasts the...
